Pre-treatment of bupivacaine-induced cardiovascular depression using different lipid formulations of propofol.
BACKGROUND
Pre-treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine, and the lipid content of propofol may alleviate bupivacaine-induced cardiotoxicity. The aim of this study is to investigate the effects of propofol in intralipid or medialipid emulsions on bupivacaine-induced cardiotoxicity.


METHODS
Rats were anaesthetised with ketamine and were given 0.5 mg/kg/min propofol in intralipid (Group P), propofol in medialipid (Group L), or saline (Group C) over 20 min. Thereafter, 2 mg/kg/min bupivacaine 0.5% was infused. We recorded time to first dysrhythmia occurrence, respective times to 25% and 50% reduction of the heart rate (HR) and mean arterial pressure, and time to asystole and total amount of bupivacaine consumption. Blood and tissue samples were collected following asystole.


RESULTS
The time to first dysrhythmia occurrence, time to 25% and 50% reductions in HR, and time to asystole were longer in Group P than the other groups. The cumulative bupivacaine dose given at those time points was higher in Group P. Plasma bupivacaine levels were significantly lower in Group P than in Group C. Bupivacaine levels in the brain and heart were significantly lower in Group P and Group L than in Group C.


CONCLUSIONS
We conclude that pre-treatment with propofol in intralipid, compared with propofol in medialipid or saline, delayed the onset of bupivacaine-induced cardiotoxic effects as well as reduced plasma bupivacaine levels. Further studies are needed to explore tissue bupivacaine levels of propofol in medialipid and adapt these results to clinical practice.
Department of Anesthesiology and Reanimation, Gazi University Faculty of Medicine, Ankara, Turkey.
M
M
Yilmaz
H
H
Celebi
D
D
Akcali
N
N
Gurel
D018686:Anesthetics, Intravenous / Q000008:administration & dosage* / Q000627:therapeutic use*; D000779:Anesthetics, Local / Q000633:toxicity*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002045:Bupivacaine / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D002626:Chemistry, Pharmaceutical; D005217:Fat Emulsions, Intravenous / Q000008:administration & dosage* / Q000627:therapeutic use*; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D015742:Propofol / Q000008:administration & dosage* / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley
D018686:Anesthetics, Intravenous; D000779:Anesthetics, Local; D005217:Fat Emulsions, Intravenous; D002045:Bupivacaine; D015742:Propofol